Clinical significance of MART-1 and HLA-A2 expression and CD8+ T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients.

Abstract

MART-1 is a good candidate antigen for immunotherapy against HLA-A2 patients with melanoma, since it is a highly immunogenic antigen recognized by HLA-A2 and HLA-B45 restricted CD8+ cytotoxic T cells and expressed in the majority of melanoma lesions. In the present study the expression of MART-1 and HLA-A2 on melanocytic cells and CD8+ T cell infiltration was immunohistochemically analyzed. MART-1 was expressed in most melanocytic lesions, while HLA-A2 was down-regulated with melanoma disease progression. Furthermore, concomitant down-regulation of MART-1 and HLA-A2 in melanoma cells was correlated with poor prognosis. These findings suggest both MART-1 and HLA-A2 expression in melanoma lesions should be analyzed for selection of patients eligible for MART-1 based immunotherapy and monitoring for emergence of melanoma cells resistant to T cell therapy.

• Authors: T Kageshita, Y Kawakami, T Ono
• Journal: Journal of dermatological science (J Dermatol Sci) Vol. 25 Issue 1 Pg. 36-44 (Jan 2001) ISSN: 0923-1811 [Print] Netherlands
• PMID: 11154862 (Publication Type: Journal Article)

Chemical References

• Antigens, Neoplasm
• HLA-A2 Antigen
• Histocompatibility Antigens Class I
• MART-1 Antigen
• MLANA protein, human
• Neoplasm Proteins

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antigens, Neoplasm
• CD8-Positive T-Lymphocytes (pathology)
• Child
• Female
• HLA-A2 Antigen (metabolism)
• Histocompatibility Antigens Class I (metabolism)
• Humans
• Immunohistochemistry (methods)
• Lymphocytes, Tumor-Infiltrating (pathology)
• MART-1 Antigen
• Male
• Melanocytes (pathology)
• Melanoma (metabolism, pathology)
• Middle Aged
• Neoplasm Proteins (metabolism)
• Skin Diseases (metabolism, pathology)
• Skin Neoplasms (metabolism, pathology)
• Staining and Labeling